Navitor Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Navitor Pharmaceuticals's estimated annual revenue is currently $1.9M per year.
- Navitor Pharmaceuticals's estimated revenue per employee is $155,000
Employee Data
- Navitor Pharmaceuticals has 12 Employees.
- Navitor Pharmaceuticals grew their employee count by 0% last year.
Navitor Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Head Business Development | Reveal Email/Phone |
3 | Chief Scientific Officer | Reveal Email/Phone |
4 | Director / Founding Scientist | Reveal Email/Phone |
5 | Director Process Chemistry | Reveal Email/Phone |
6 | Technical Consultant | Reveal Email/Phone |
Navitor Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Navitor Pharmaceuticals?
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company's proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell's response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor's therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company's founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.
keywords:N/A
N/A
Total Funding
12
Number of Employees
$1.9M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 12 | 0% | $16.4M |
#2 | N/A | 12 | 9% | N/A |
#3 | $1.5M | 12 | 0% | N/A |
#4 | $1.8M | 12 | -43% | N/A |
#5 | $1.3M | 12 | -8% | N/A |